Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2016 Jan;4(1):706-715.
Epub 2016 Jan 1.

Hypoxia inducible factor-1 alpha and multiple myeloma

Archana Bhaskar  1 , Bhupendra Nath Tiwary  1
Affiliations

"V体育官网入口" Hypoxia inducible factor-1 alpha and multiple myeloma

Archana Bhaskar et al. Int J Adv Res (Indore). 2016 Jan.

Abstract

Rapid tumor growth creates a state of hypoxia in the tumor microenvironment and results in release of hypoxia inducible factor-1 alpha (HiF-1α) in the local milieu. Hypoxia inducible factor activity is deregulated in many human cancers, especially those that are highly hypoxic. In multiple myeloma (MM) in initial stages of disease establishment, the hypoxic bone marrow microenvironment supports the initial survival and growth of the myeloma cells. Hypoxic tumour cells are usually resistant to radiotherapy and most conventional chemotherapeutic agents, rendering them highly aggressive and metastatic. Therefore, HIF is an attractive, although challenging, therapeutic target in MM directly or indirectly in recent years. VSports手机版.

Keywords: Angiogenesis; Angiogenic regulator; Hypoxia; Hypoxia inducible factor-1 alpha (HiF-1α); Multiple myeloma (MM) V体育安卓版. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
The oxygen-dependent regulation of the HIF complex (adapted from Cook and Fig 2010). PHD, prolyl hydroxylase; FIH, factor inhibiting HIF; OH, hydroxylated amino acid residues
See this image and copyright information in PMC

References

    1. Abd-Aziz N, Stanbridge EJ, Shafee N. Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation. Oncol Lett. 2015;10:2192–2196. - PMC - PubMed
    1. Asosingh K, De Raeve H, de Ridder M, Storme GA, Willems A, Van Riet I, Van Camp B, Vanderkerken K. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica. 2005;90:810–17. - V体育平台登录 - PubMed
    1. Bhaskar A, Gupta R, Kumar L, Sharma A, Sharma MC, Kalaivani M, Thakur SC. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk Lymphoma. 2012;53:635–640. - PubMed
    1. Bhaskar A, Gupta R, Sreenivas V, Kumar L, Sharma A, Sharma MC, Das P, Thakur SC. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma. 2013;54:1473–1478. - PubMed
    1. Bhaskar A, Gupta R, Sreenivas V, Kumar L, Sharma A, Thakur SC. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res. 2013;37:410–415. - PubMed (V体育官网入口)

LinkOut - more resources